Knott David M Jr purchased a new position in shares of Cybin Inc. (NYSE:CYBN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 60,446 shares of the company's stock, valued at approximately $533,000. Knott David M Jr owned approximately 0.30% of Cybin at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in CYBN. Fore Capital LLC lifted its holdings in shares of Cybin by 70.6% during the fourth quarter. Fore Capital LLC now owns 31,421 shares of the company's stock valued at $277,000 after acquiring an additional 13,000 shares during the period. Diametric Capital LP acquired a new stake in shares of Cybin during the 4th quarter worth about $157,000. Essential Planning LLC. bought a new position in Cybin during the 4th quarter valued at about $138,000. Cowa LLC acquired a new position in Cybin in the fourth quarter valued at about $115,000. Finally, Global Retirement Partners LLC bought a new stake in Cybin during the 4th quarter worth approximately $46,000. Institutional investors own 17.94% of the company's stock.
Cybin Price Performance
Shares of CYBN traded down $0.27 on Friday, reaching $5.69. 323,084 shares of the company's stock were exchanged, compared to its average volume of 222,109. The stock's 50 day simple moving average is $8.27. Cybin Inc. has a 12 month low of $5.53 and a 12 month high of $17.48. The stock has a market cap of $122.20 million, a PE ratio of -1.30 and a beta of 0.61.
Analyst Ratings Changes
A number of brokerages have weighed in on CYBN. Guggenheim initiated coverage on shares of Cybin in a research note on Thursday, March 13th. They issued a "buy" rating and a $35.00 target price for the company. Canaccord Genuity Group decreased their price objective on Cybin from $86.00 to $73.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th. Finally, HC Wainwright dropped their target price on Cybin from $190.00 to $150.00 and set a "buy" rating for the company in a research report on Thursday, February 13th.
View Our Latest Report on CYBN
Cybin Profile
(
Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
Further Reading
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
